SVF
Level A· Stronger Clinical EvidenceSystematic Review

Autologous lipotransfer for bone defects secondary to osteomyelitis: A report of a novel method and systematic review of the literature.

Reinisch KB., Zuk G., Raptis DA., Bueter M., Guggenheim M., Stasch T.

Systematic Review on Ankle Injury, Chronic Wound, Immune Modulation, published in Int Wound J (2019) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Int Wound J (2019)
Country
England
Reported sample size
—
PMID
30916475
DOI
10.1111/iwj.13119

Abstract (original English)

Autologous bone grafting is the gold standard in patients with bone defects but is associated with significant pain and donor site morbidity. Autologous lipotransfer (fat grafting or lipofilling) has become very popular in the therapy of chronic wounds. Mesenchymal stem cells from adipose tissue are known for their regenerative, reparative, and immunomodulatory effects. This case study and review evaluates the use of autologous lipotransfer for chronic osteomyelitis in a 26-year-old patient. A 26-year-old female suffering from chronic tibial osteomyelitis was initially treated with surgical debridement and antibiotics followed by lipoharvest and autologous lipofilling. MRI and computed tomography scans were performed at 2 and 6 weeks and 6 months postoperatively. A formal systematic review of clinical trials investigating autologous lipotransfer for osteomyelitis was conducted. The patient remained asymptomatic without recurrence, and the bone defect cavity showed vascularised adipose tissue after 6 weeks, with early signs of osteogenesis. The highest foot and ankle disability index was 100. The systematic review identified 266 studies after duplicates were removed. After screening for eligibility, seven manuscripts were further assessed, with none meeting the inclusion criteria. This is the first study to report the successful use of autologous lipotransfer with early signs of

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Adipose TissueAdultBone DiseasesFemaleHumansOsteomyelitisPlastic Surgery ProceduresTransplantation, AutologousTreatment Outcome
Ankle & FootAnkle InjuryChronic WoundImmune Modulation
View on PubMedDOI

Related research